MRVI

Maravai Lifesciences Holdings Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$2.51B
P/E Ratio
—
EPS
$-0.53
Beta
0.54
52W High
$9.42
52W Low
$2.54
50-Day MA
$7.21
200-Day MA
$5.04
Dividend Yield
—
Profit Margin
-37.10%
Forward P/E
370.37
PEG Ratio
—

About Maravai Lifesciences Holdings Inc

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$208.78M
Gross Profit (TTM)$74.55M
EBITDA$-19.75M
Operating Margin-29.40%
Return on Equity-33.10%
Return on Assets-5.71%
Revenue/Share (TTM)$1.43
Book Value$1.37
Price-to-Book5.37
Price-to-Sales (TTM)12.05
EV/Revenue5.77
EV/EBITDA1.77
Quarterly Earnings Growth (YoY)-32.70%
Quarterly Revenue Growth (YoY)8.50%
Shares Outstanding$148.99M
Float$106.40M
% Insiders7.23%
% Institutions99.56%

Historical Volatility

HV 10-Day
93.70%
HV 20-Day
73.50%
HV 30-Day
66.52%
HV 60-Day
80.71%
HV Rank
63.5%

Volatility is currently expanding

Analyst Ratings

Consensus ($8.50 target)
4
Buy
4
Hold

Latest News

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav.

Business Wire10/14/2026Neutral
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands.

Business Wire9/29/2026Neutral
Maravai LifeSciences Q2 Earnings Call Highlights

Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.

MarketBeat8/7/2026Positive
Maravai LifeSciences Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.

Business Wire8/6/2026Neutral
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.

Business Wire7/22/2026Neutral
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical com.

Business Wire7/20/2026Neutral
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.

Business Wire6/16/2026Neutral
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.

Business Wire6/3/2026Neutral
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.

Business Wire5/18/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRVI and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 10/17/2026